Clinical trial · Observational
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Absolute Quantification of c-Kit Mutation as MRD in Acute Myeloid Leukemia: a Prospective Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The test for c-kit was not set up and replaced by NGS MRD
Summary
Brief summary (as posted)
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitoring is still unclear. What are the differences and advantages of using c-Kit mutation as MRD in prognostic assessment compared with other MRDs (MFC or RUNX1::RUNX1T1) widely used today? Existing data suggest that patients with one positive and one negative MRD results obtained by two different techniques have a higher risk of recurrence than patients with two negative MRD results but a lower risk of recurrence than patients with two positive MRD results. Therefore, can combining multiple MRD markers, including c-Kit mutations, overcome the shortcomings of a single molecular marker as MRD monitoring? Therefore, this project intends to confirm the clinical significance of quantitative detection of c-Kit mutation as MRD in acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| C-KIT Mutation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (5)
- label
- MRD negative
- description
- c-Kit mutation tested negative
- label
- MRD L1
- description
- MRD detection at low level-1：\<0.001%
- label
- MRD L2
- description
- MRD detection at low level-2：0.001%≤c-Kit MRD\<0.01%
- label
- MRD L3
- description
- detection at low level-3：0.01%≤c-Kit MRD\<0.1%
- label
- MRD positive
- description
- MRD positive：c-Kit MRD≥0.1%
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: Patients who meet the diagnostic criteria(WHO 2016 criteria) of AML and have c-Kit D816 mutation. And receive treatment. Exclusion Criteria: Patients with other factors which were considered unsuitable to participate in the study by the investigators
References
Publications (0)
Data not yet available